TICKERNERD
Menu
INABINABHealthcare · Biotechnology

INAB Stock Forecast: IN8bio, Inc. Price Predictions for 2026-2027

Last close, 13 Nov 2026
$0.84
+1.84% on the day

The 3 Wall Street analysts covering IN8bio, Inc. hold a median 12-month price target of $6 — +618.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 31 of 100 as at 13 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$8.9M
Ticker Nerd rank
31/ 100
Median analyst target
$6.00
Analysts covering
3
Revenue$0.0
Operating income−$4.9M
Net income−$4.8M
Free cash flow−$4.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.9%
1M
−29.2%
YTD
−64.3%
1Y
−49.1%
From 52W high
−67.8%
From 52W low
+1.8%
$0.82
$2.59
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

INAB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores IN8bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Nov 2026
31/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
91
Accruals
82
Quality
48
Growth
41
Volatility
38
Issuance
38
Revisions
28
Momentum
18
Value
14

Size (91): Smaller than most of the companies we track.

Value (14): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

INAB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on INAB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Jan 26Apr 26Jul 26Oct 26INABHigh $10.00Median $6.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $5.00Median $6.00High $10.00

The green dot is the last close — the median target sits +618.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 Mar 2026HC Wainwright & Co.ReiteratesBuy$6.00
14 Mar 2025HC Wainwright & Co.MaintainsBuy—
12 Feb 2025HC Wainwright & Co.ReiteratesBuy—
11 Feb 2025Jones TradingUpgradeBuy—
26 Nov 2024HC Wainwright & Co.ReiteratesBuy—
13 Nov 2024HC Wainwright & Co.MaintainsBuy—
12 Aug 2024Jones TradingDowngradeHold—
14 June 2024HC Wainwright & Co.ReiteratesBuy—
14 June 2024Jones TradingMaintainsBuy—
4 June 2024HC Wainwright & Co.ReiteratesBuy—
13 May 2024HC Wainwright & Co.MaintainsBuy—
10 Apr 2024HC Wainwright & Co.ReiteratesBuy—
18 Mar 2024Laidlaw & Co.InitiatesBuy—
15 Mar 2024HC Wainwright & Co.ReiteratesBuy—
13 Mar 2024JonesTradingInitiatesBuy—
13 Nov 2023HC Wainwright & Co.ReiteratesBuy—
11 Aug 2023HC Wainwright & Co.ReiteratesBuy—
5 June 2023EF HuttonReiteratesBuy—
16 May 2023HC Wainwright & Co.ReiteratesBuy—
26 Apr 2023HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

INAB appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

INAB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 13 Nov 2026, IN8bio, Inc. returned −49.1% against +13.4% for the S&P 500, dividends included.

INAB vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140160Jan 26Apr 26Jul 26Oct 26INABS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

INAB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
2
Fundamentals

IN8bio, Inc. (INAB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.2×

Cheaper than 79% of US stocks

Price / sales
—
Price / book
0.6×

Cheaper than 81% of US stocks

EV / EBITDA
0.1×

Cheaper than 62% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−141.8%

Higher than 10% of US stocks

Return on assets
−70.3%

Higher than 5% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

IN8bio, Inc. (INAB) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • IN8bio, Inc. has a market value of $8.9M and an enterprise value of −$2.4M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$18.7M.

  • Free cash flow in the twelve months to 30 June 2026: −$14.6M.

  • Shares outstanding: 9.8M.

  • Trailing P/E: −0.2×; forward P/E: −0.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • IN8bio, Inc. employs 17 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Nov 2026

Data provided by Twelve Data

Peers

INAB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
INABIN8bio, Inc.$8.9M31
PHIOPhio Pharmaceuticals Corp.$9.0M28
AEONAEON Biopharma, Inc.$9.0M45
MTVAMetaVia, Inc.$8.6M17
LEXXLexaria Bioscience Corp.$9.4M19
MBRXMoleculin Biotech, Inc.$8.3M21
CALCCalciMedica, Inc.$8.3M37

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own IN8bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest INAB news & analysis

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 6 Nov 2026neutral

IN8bio granted one employee a nonqualified stock option to purchase 4,000 shares under its 2026 Inducement Plan. The grant was approved by the Compensation Committee, dated November 2, 2026, and made as an employment inducement under Nasdaq Listing Rule 5635(c)(4).

Why it matters — The grant is a compensation and hiring-related disclosure that INAB watchers may note as part of the company's equity awards.

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 6 Oct 2026neutral

IN8bio granted one new employee a nonqualified stock option to purchase 60,000 shares. The award was granted under its 2026 Inducement Plan on October 1, 2026, as an inducement to employment under Nasdaq Listing Rule 5635(c)(4).

Why it matters — INAB watchers may note the share-based compensation award and its potential effect on the company’s outstanding equity.

IN8bio to Present at Sidoti Small-Cap Virtual Conference

GlobeNewsWire · 22 Sept 2026neutral

IN8bio announced that CEO William Ho will participate in the Sidoti Small-Cap Virtual Conference held September 23-24, 2026. The clinical-stage biopharmaceutical company develops gamma-delta T cell therapies and T cell engagers for cancer and autoimmune diseases.

Why it matters — INAB watchers may be interested because the CEO's conference participation provides company exposure to the small-cap investment community without any operational or financial details.

IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 10 Sept 2026neutral

IN8bio announced that CEO and Co-Founder William Ho will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference. The company is a clinical-stage biopharmaceutical firm developing gamma-delta T cell therapies and T cell engagers for cancer and autoimmune diseases.

Why it matters — The CEO's participation provides an opportunity for IN8bio to present its pipeline and strategic direction to investors at a major investment conference.

IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development

GlobeNewsWire · 9 Sept 2026positive

IN8bio announced the appointment of Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development. Polyakova is a renowned expert in γδ T cells and T cell engagers with two decades of drug discovery and development experience, and will join as the company advances its γδ T cell engager platform.

Why it matters — IN8bio watchers would care because the appointment brings specialized domain expertise in γδ T cells and T cell engagers to strengthen the company's leadership as it advances its novel platform.

FAQ

Frequently asked questions about INAB stock

What is the INAB stock price forecast for 2026-2027?

The 3 Wall Street analysts covering IN8bio, Inc. have a median 12-month price target of $6, with estimates ranging from $5 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is INAB stock a buy right now?

Of the 3 analysts covering IN8bio, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks IN8bio, Inc. 31 out of 100 across roughly 4,600 US stocks as at 13 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank INAB?

As at 13 Nov 2026, IN8bio, Inc. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (91 of 100).

Will INAB stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +618.5% from the last close, and Ticker Nerd's factor model ranks IN8bio, Inc. 31 out of 100 as at 13 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the INAB stock forecast for 2030?

No analyst covering IN8bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INAB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $10 over the next 12 months.

How has INAB stock performed over the past year?

IN8bio, Inc. returned -49.1% over the 12 months to 13 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does IN8bio, Inc. do?

IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on developing gamma-delta T cell therapies and T cell engagers for cancer and autoimmune diseases.

What is the latest news on INAB?

The most recent item we track (GlobeNewsWire, 6 Nov 2026): "IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)". IN8bio granted one employee a nonqualified stock option to purchase 4,000 shares under its 2026 Inducement Plan. The grant was approved by the Compensation Committee, dated November 2, 2026, and made as an employment inducement under Nasdaq Listing Rule 5635(c)(4).

Company

About IN8bio, Inc.

IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on developing gamma-delta T cell therapies and T cell engagers for cancer and autoimmune diseases. IN8bio’s current pipeline centers on cell-based immunotherapies designed to target solid and hematologic tumors, with programs spanning allogeneic, autologous, iPSC-derived, and genetically modified approaches. Its lead and clinical programs include candidates being studied in glioblastoma and leukemia settings, reflecting the company’s emphasis on difficult-to-treat cancers and unmet medical needs. IN8bio also advances a T cell engager platform intended to broaden the reach of its immunotherapy portfolio across oncology and autoimmune indications. Based in New York, IN8bio plays a niche role in the biotechnology market as a developer of next-generation cellular medicines.

CEO Mr. Tai-Wei Ho · 17 employees · United States · https://in8bio.com